Substituted Heterocycles Inhibit c-MYC via MYC/Max DNA Binding Interference
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current approaches to targeting the c-MYC oncogene for cancer treatment are hindered by its classification as 'undruggable' due to difficulties in inhibiting transcription factors with small molecules, limiting the development of effective anti-cancer strategies.
Innovation Solution
Development of substituted heterocycles, specifically pyrazoles, pyrimidines, and triazoles, which selectively target c-MYC-driven cell proliferation by interfering with the binding of the MYC/Max complex to DNA, offering a novel approach to inhibit c-MYC activity without causing significant DNA damage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If transcription factors like c-MYC are targeted with small molecules, then cancer cell proliferation can be inhibited, but the difficulty of targeting transcription factors makes this approach currently regarded as undruggable
Solution Approach 1:
The patent employs an intermediary approach by designing small molecules that do not directly bind to the transcription factor c-MYC itself, but rather to the c-MYC/Max heterodimer complex or to DNA regions where c-MYC binds, thereby indirectly inhibiting c-MYC function. This intermediary strategy circumvents the difficulty of directly targeting transcription factors while achieving reliable cancer cell proliferation inhibition.
2Productivity
If small molecule inhibitors are developed to target c-MYC, then anti-cancer strategy effectiveness can be improved, but the current inability to effectively target transcription factors limits this approach
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure, binding affinity, and selectivity parameters of small molecule compounds to optimize their ability to inhibit c-MYC activity. By systematically varying molecular parameters such as heterocyclic ring types, substituent groups, and binding constants, the invention achieves effective anti-cancer productivity while maintaining drug development feasibility through structure-activity relationship optimization.
3Reliability
If substituted heterocycles are designed to interfere with c-MYC binding to DNA, then selective inhibition of c-MYC-driven cell proliferation is achieved, but the complexity of achieving selectivity increases
Solution Approach 1:
The patent applies local quality by introducing specific substituent groups at particular positions on the heterocyclic core structure to enhance selectivity for c-MYC binding. Different substituents (such as halogens, alkyl groups, or functional groups) are placed at specific locations on the molecule to create localized interactions with the c-MYC/Max complex or DNA, thereby achieving high selectivity for c-MYC-driven cells without requiring overly complex overall molecular structures.
Data Source
AI summary
Disclosed are substituted heterocycle compounds including substituted pyrazoles, substituted pyrimidines, and substitute triazoles. The substituted heterocycles disclosed herein are shown to be useful in inhibiting c-MYC and may be utilized as therapeutics for treating cancer and cell proliferative disorders.